Please assess the completion status of the following clinical trial:

Trial Title: Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Adult patients (age ≥ 18 years) with hyponatremia (\<133mmol/l) due to chronic (\>72h) SIADH defined as~* serum osmolality \<275mosm/kg~* urine osmolality \>100mosm/kg~* urine sodium \>30mmol/l~Exclusion Criteria:~* acute (\<72h) or transient hyponatremia~* severe symptomatic hyponatremia in need of hospital treatment~* diabetes mellitus type 1~* uncontrolled hypothyroidism~* uncontrolled adrenal insufficiency~* renal impairment (GFR \<45ml/min)~* cardiac failure~* symptomatic liver disease / severe hepatic impairment (ALAT / aspartate transaminase (ASAT) \> 3x upper limit)~* treatment with SGLT 2 inhibitors, lithium chloride, urea or glitazone~* severe immunosuppression~* pregnancy or breastfeeding~* palliative situation (end of life care)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Empagliflozin (Type: ACTIVE_COMPARATOR): Treatment with empagliflozin 25mg tablets once daily for 28 days
- Placebo (Type: PLACEBO_COMPARATOR): Treatment with Placebo tablets once daily for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).